Breakthrough Antivenom Developed from Blood of Man Bitten Over 200 Times

In a remarkable development within medical science, researchers have unveiled a groundbreaking antivenom derived from the blood of Tim Friede, a US man who voluntarily injected himself with snake venom for nearly 18 years. This innovative antivenom is being touted as "unparalleled" due to its ability to protect against venom from numerous species, according to scientists involved in the study. Current antivenom therapies are often species-specific; however, Friede’s unique antibodies could represent a significant leap towards a universal remedy against snake bites, which claim the lives of approximately 14,000 individuals annually while leaving many others facing severe disabilities.Over the course of his 18-year quest, Friede has endured more than 200 snake bites and approximately 700 venom injections from some of the world's most dangerous snakes, including various species of mambas, cobras, and taipans. His initial goal was to build immunity for personal safety while handling snakes, a process he chronicled on social media. However, a near-fatal incident involving consecutive cobra bites ignited his resolve to develop better antivenoms for others at risk.Antivenom production typically involves administering small quantities of venom to animals like horses, prompting immune responses that produce antibodies against specific venoms. This method requires precise matching between antivenom and snake species due to substantial variability in venom compositions. In contrast, researchers are now pursuing broadly neutralizing antibodies that can target common components across different classes of toxins. Dr. Jacob Glanville, chief executive of Centivax, recognizes Friede as a vital link in this research endeavor, expressing eagerness to study his unique blood. After obtaining ethical approval for collecting blood samples rather than administering more venom, researchers analyzed the protective capabilities of the antibodies found in Friede’s blood. Their focus was on elapids, a family of venomous snakes, which utilize neurotoxins to incapacitate their prey and can be lethal when respiratory muscles are affected.Through meticulous examination, scientists identified two broadly neutralizing antibodies capable of targeting specific neurotoxin classes. By combining these with a drug targeting another class, they formulated a new antivenom cocktail that successfully protected mice from lethal doses of venom from 13 out of 19 tested elapid species, with partial protection against the remaining six."This breadth of protection is unrivaled," stated Dr. Glanville, who believes this research could potentially address the lack of effective antivenoms for many elapid snakes. Researchers are now working on refining the formulas further and hope to produce an antivenom that is effective against all elapid and viper snake venoms within the next 10 to 15 years. Prof. Peter Kwong, a key researcher, noted that Friede’s antigens are exceptionally broad in recognition capabilities, raising hopes for a more comprehensive treatment approach.While the findings are promising, experts, including Prof. Nick Casewell from the Liverpool School of Tropical Medicine, caution that extensive testing remains necessary before the antivenom can be administered to humans. Nevertheless, for Friede, the progress made so far is fulfilling. “I’m doing something good for humanity, and that was very important to me," he said, reflecting on his unconventional journey that seeks to benefit snakebite victims worldwide.